trending Market Intelligence /marketintelligence/en/news-insights/trending/2SCzzilb0zO-wikdYFNMGg2 content esgSubNav
In This List

GSK, VBI Vaccines initiate collaboration to study drug combo for brain cancer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GSK, VBI Vaccines initiate collaboration to study drug combo for brain cancer

VBI Vaccines Inc. and GlaxoSmithKline PLC started a partnership to evaluate a combination of VBI's cancer vaccine VBI-1901 with GSK's proprietary AS01B.

Under the collaboration, VBI intends to add another study group to part B of its ongoing phase 1/2a study of VBI-1901 as a treatment for recurrent glioblastoma, an aggressive type of brain tumor associated with infection caused by a common virus called cytomegalovirus.

Patients in part B will receive VBI-1901 in combination with either Partner Therapeutics Inc.'s Leukine or AS01B.

Leukine and AS01B are both immunomodulatory adjuvants, additional chemical agents that modify the immune response by stimulating antibody formation or inhibiting white blood cell activity.

Cambridge, Mass.-based VBI will enroll 20 patients with recurrent glioblastoma in part B of the trial. It started the enrollment in the Leukine arm at the end of July and expects to start enrolling patients in the AS01B arm in the second half of the year.

Emmanuel Hanon, senior vice president and head of research and development at GSK Vaccines, said it is the first time the company has partnered with a biopharma company to evaluate AS01B in a clinical setting.

VBI's stock price was up 13.68% to 64 cents as of 2:16 p.m. ET on Sept. 10.